Literature DB >> 23324657

Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men.

Markella V Zanni1, Suhny Abbara, Janet Lo, Bryan Wai, David Hark, Eleni Marmarelis, Steven K Grinspoon.   

Abstract

OBJECTIVE: Among HIV-infected patients, high rates of myocardial infarction (MI) and sudden cardiac death have been observed. Exploring potential underlying mechanisms, we used multidetector spiral coronary computed tomography angiography (coronary CTA) to compare atherosclerotic plaque morphology in HIV-infected patients and non-HIV-infected controls.
METHODS: Coronary atherosclerotic plaques visualized by CTA in HIV-infected (101) and non-HIV-infected (41) men without clinically apparent heart disease matched on cardiovascular risk factors were analyzed for three vulnerability features: low attenuation, positive remodeling, and spotty calcification.
RESULTS: Ninety-five percent of HIV-infected patients were receiving ART (median duration 7.9 years) and had well controlled disease (median CD4 cell count, 473 cells/μl; median HIV RNA <50 copies/ml). Age and traditional cardiovascular risk factors were similar in HIV-infected patients and controls. Among the HIV-infected (versus control) group, there was a higher prevalence of patients with at least one: low attenuation plaque (22.8 versus 7.3%, P = 0.02), positively remodeled plaque (49.5 versus 31.7%, P = 0.05) and high-risk 3-feature plaque (7.9 versus 0%, P = 0.02). Moreover, patients in the HIV-infected (versus control) group demonstrated a higher number of low attenuation plaques (P = 0.01) and positively remodeled plaques (P = 0.03) per patient.
CONCLUSION: Our data demonstrate an increased prevalence of vulnerable plaque features among relatively young HIV-infected patients. Differences in coronary atherosclerotic plaque morphology - namely, increased vulnerable plaque among HIV-infected patients - are here for the first time reported and may contribute to increased rates of MI and sudden cardiac death in this population.

Entities:  

Mesh:

Year:  2013        PMID: 23324657      PMCID: PMC3740057          DOI: 10.1097/QAD.0b013e32835eca9b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  37 in total

1.  Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.

Authors:  Colette Smith; Caroline A Sabin; Jens D Lundgren; Rodolphe Thiebaut; Rainer Weber; Matthew Law; Antonella d'Arminio Monforte; Ole Kirk; Nina Friis-Moller; Andrew Phillips; Peter Reiss; Wafaa El Sadr; Christian Pradier; Signe W Worm
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

2.  Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography.

Authors:  Masaya Shimojima; Masa-Aki Kawashiri; Yutaka Nitta; Taiji Yoshida; Shouji Katsuda; Bunji Kaku; Tomio Taguchi; Akira Hasegawa; Tetsuo Konno; Kenshi Hayashi; Masakazu Yamagishi
Journal:  Am J Cardiovasc Dis       Date:  2012-05-15

3.  A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps.

Authors:  Yuliya Vengrenyuk; Stéphane Carlier; Savvas Xanthos; Luis Cardoso; Peter Ganatos; Renu Virmani; Shmuel Einav; Lane Gilchrist; Sheldon Weinbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

4.  Non-obstructive low attenuation coronary plaque predicts three-year acute coronary syndrome events in patients with hypertension: multidetector computed tomographic study.

Authors:  Koki Nakanishi; Shota Fukuda; Kenei Shimada; Shoichi Ehara; Hitoshi Inanami; Kenji Matsumoto; Haruyuki Taguchi; Takashi Muro; Junichi Yoshikawa; Minoru Yoshiyama
Journal:  J Cardiol       Date:  2012-01-14       Impact factor: 3.159

5.  Arterial inflammation in patients with HIV.

Authors:  Sharath Subramanian; Ahmed Tawakol; Tricia H Burdo; Suhny Abbara; Jeffrey Wei; Jayanthi Vijayakumar; Erin Corsini; Amr Abdelbaky; Markella V Zanni; Udo Hoffmann; Kenneth C Williams; Janet Lo; Steven K Grinspoon
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

6.  Coronary risk factors and plaque morphology in men with coronary disease who died suddenly.

Authors:  A P Burke; A Farb; G T Malcom; Y H Liang; J Smialek; R Virmani
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

Review 7.  Innate and adaptive immunity in atherosclerosis.

Authors:  René R S Packard; Andrew H Lichtman; Peter Libby
Journal:  Semin Immunopathol       Date:  2009-05-16       Impact factor: 9.623

8.  Characterization of noncalcified coronary plaques and identification of culprit lesions in patients with acute coronary syndrome by 64-slice computed tomography.

Authors:  Toshiro Kitagawa; Hideya Yamamoto; Jun Horiguchi; Norihiko Ohhashi; Futoshi Tadehara; Tomoki Shokawa; Yoshihiro Dohi; Eiji Kunita; Hiroto Utsunomiya; Nobuoki Kohno; Yasuki Kihara
Journal:  JACC Cardiovasc Imaging       Date:  2009-02

9.  Ex vivo coronary atherosclerotic plaque characterization with multi-detector-row CT.

Authors:  Christoph R Becker; Konstantin Nikolaou; Michael Muders; Gregor Babaryka; Alexander Crispin; U Joseph Schoepf; Udo Loehrs; Maximilian F Reiser
Journal:  Eur Radiol       Date:  2003-04-12       Impact factor: 5.315

Review 10.  Immunologic basis of cardiovascular disease in HIV-infected adults.

Authors:  Priscilla Y Hsue; Steven G Deeks; Peter W Hunt
Journal:  J Infect Dis       Date:  2012-06       Impact factor: 5.226

View more
  66 in total

1.  Cardiovascular disease in HIV: traditional and nontraditional risk factors.

Authors:  Steven K Grinspoon
Journal:  Top Antivir Med       Date:  2014 Sep-Oct

2.  Preventing Heart Failure in Inflammatory and Immune Disorders.

Authors:  Maya Serhal; Chris T Longenecker
Journal:  Curr Cardiovasc Risk Rep       Date:  2014-06

3.  Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men.

Authors:  Anne K Monroe; Wei Fu; Michelle N Zikusoka; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Lawrence A Kingsley; Wendy S Post; Todd T Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2015-03-09       Impact factor: 2.205

Review 4.  Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.

Authors:  Avanthi Raghavan; Dodie E Rimmelin; Kathleen V Fitch; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

Review 5.  Inflammation, immune activation, and cardiovascular disease in HIV.

Authors:  Eric Nou; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

6.  2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque.

Authors:  Markella V Zanni; Kathleen V Fitch; Meghan Feldpausch; Allison Han; Hang Lee; Michael T Lu; Suhny Abbara; Heather Ribaudo; Pamela S Douglas; Udo Hoffmann; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

Review 7.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

8.  Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Authors:  Udo Hoffmann; Michael T Lu; Devvora Olalere; Elizabeth C Adami; Michael T Osborne; Alex Ivanov; John Sukumar Aluru; Saeyun Lee; Nadja Arifovic; Edgar Turner Overton; Carl J Fichtenbaum; Judith A Aberg; Beverly Alston-Smith; Karin L Klingman; Myron Waclawiw; Tricia H Burdo; Kenneth C Williams; Markella V Zanni; Patrice Desvigne-Nickens; Katharine Cooper-Arnold; Kathleen V Fitch; Heather Ribaudo; Pamela S Douglas; Steven K Grinspoon
Journal:  Am Heart J       Date:  2019-03-04       Impact factor: 4.749

9.  Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Authors:  Steven K Grinspoon; Kathleen V Fitch; Edgar Turner Overton; Carl J Fichtenbaum; Markella V Zanni; Judith A Aberg; Carlos Malvestutto; Michael T Lu; Judith S Currier; Craig A Sponseller; Myron Waclawiw; Beverly Alston-Smith; Katharine Cooper-Arnold; Karin L Klingman; Patrice Desvigne-Nickens; Udo Hoffmann; Heather J Ribaudo; Pamela S Douglas
Journal:  Am Heart J       Date:  2019-03-04       Impact factor: 4.749

Review 10.  The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.

Authors:  Frederick O Cope; Bonnie Abbruzzese; James Sanders; Wendy Metz; Kristyn Sturms; David Ralph; Michael Blue; Jane Zhang; Paige Bracci; Wiam Bshara; Spencer Behr; Toby Maurer; Kenneth Williams; Joshua Walker; Allison Beverly; Brooke Blay; Anirudh Damughatla; Mark Larsen; Courtney Mountain; Erin Neylon; Kaeli Parcel; Kapil Raghuraman; Kevin Ricks; Lucas Rose; Akhilesh Sivakumar; Nicholas Streck; Bryan Wang; Christopher Wasco; Larry S Schlesinger; Abul Azad; Murugesan V S Rajaram; Wael Jarjour; Nicholas Young; Thomas Rosol; Amifred Williams; Michael McGrath
Journal:  Nucl Med Biol       Date:  2015-12-03       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.